Nektar Therapeutics Framtida tillväxt
Future kriterier kontrolleras 2/6
Nektar Therapeutics s intäkter förväntas minska med 16.9% per år medan dess årliga intäkter förväntas växa med 34% per år. EPS förväntas falla med 5% per år. Avkastningen på eget kapital förväntas bli -52.4% om 3 år.
Viktig information
-16.9%
Tillväxttakt i vinsten
-4.99%
Tillväxttakt för EPS
| Pharmaceuticals vinsttillväxt | 14.4% |
| Intäkternas tillväxttakt | 34.0% |
| Framtida avkastning på eget kapital | -52.38% |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 13 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • May 18
NKTR: Future Phase 3 Autoimmune Data Will Drive Upside Repricing Potential
Narrative Update on Nektar Therapeutics The updated analyst price target for Nektar Therapeutics has shifted from a fair value of $165.00 to $192.00 as analysts factor in recent target changes across the Street and revisit assumptions around revenue growth, profit margins, discount rate and future P/E multiples. Analyst Commentary Recent Street research around Nektar Therapeutics clusters around the potential of its lead asset rezpegaldesleukin in atopic dermatitis and alopecia areata, as well as the implications for long term revenue and earnings power.Analysartikel • May 11
Earnings Update: Here's Why Analysts Just Lifted Their Nektar Therapeutics (NASDAQ:NKTR) Price Target To US$153
Shareholders might have noticed that Nektar Therapeutics ( NASDAQ:NKTR ) filed its quarterly result this time last...
Uppdatering av berättelse • May 01
NKTR: Phase 3 Atopic Dermatitis And Alopecia Data Will Drive Future Upside
Analysts have lifted Nektar Therapeutics' fair value estimate from $128.13 to $144.25 as multiple firms raised their price targets, pointing to rezpegaldesleukin data, an expanded Phase 3 plan in atopic dermatitis, and a clearer funding path as key drivers of their updated views. Analyst Commentary Recent Street research on Nektar Therapeutics has focused on rezpegaldesleukin, the planned Phase 3 program in atopic dermatitis, and updated funding assumptions, with several firms updating models and price targets.Uppdatering av berättelse • Apr 16
NKTR: Future Phase 3 Atopic Dermatitis Data Will Drive Upside Repricing Potential
Analysts have lifted the base case fair value estimate for Nektar Therapeutics from $135 to $165, citing recent Street research that highlights rezpeg data in atopic dermatitis and alopecia, a Phase 3 plan in atopic dermatitis, and a series of higher price targets and upgrades across multiple firms. Analyst Commentary Recent Street research on Nektar Therapeutics has tilted clearly positive, with several firms lifting price targets and highlighting rezpegaldesleukin, or rezpeg, as the key driver for their valuation work.Seeking Alpha • Apr 15
Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive
Summary Nektar Therapeutics is poised for a key catalyst with upcoming REZPEG 52-week maintenance data in Alopecia Areata (AA) before April’s end. My base case model projects REZPEG will achieve a probability-adjusted 28% of patients reaching SALT <20, matching or exceeding low-dose baricitinib efficacy. REZPEG’s benign safety profile and lack of black box warning may offset slightly lower efficacy compared to JAK inhibitors in AA. A positive 52-week readout could drive NKTR shares 30–40% higher, as current valuation barely reflects AA potential. Read the full article on Seeking AlphaUppdatering av berättelse • Apr 01
NKTR: Phase 3 Atopic Dermatitis Program And Data Strength Will Drive Future Upside
The analyst price target for Nektar Therapeutics has been adjusted from $136.43 to $128.13 as analysts factor in updated rezpegaldesleukin Phase 2 data, plans for a Phase 3 atopic dermatitis study, and recent Street research that refines expectations around future sales potential and valuation multiples. Analyst Commentary Recent Street research around Nektar Therapeutics clusters around rezpegaldesleukin, with analysts updating models on the back of Phase 2 atopic dermatitis data, longer term maintenance results and the planned Phase 3 program.Uppdatering av berättelse • Mar 18
NKTR: Phase 3 Atopic Dermatitis Program Will Drive Future Upside Potential
The analyst fair value estimate for Nektar Therapeutics has shifted from $129.86 to $136.43, as analysts factor in higher modeled sales potential for rezpegaldesleukin in atopic dermatitis and alopecia, along with recent price target increases across several firms tied to progressing Phase 2 data and planned Phase 3 programs. Analyst Commentary Recent Street research around Nektar Therapeutics has focused on rezpegaldesleukin, with pricing models and risk assessments concentrating on its potential role in atopic dermatitis and alopecia as Phase 2 data matures and Phase 3 plans move forward.Uppdatering av berättelse • Mar 04
NKTR: Rezpeg Durability In Atopic Dermatitis And Alopecia Will Drive Future Upside
Analysts have lifted their price targets on Nektar Therapeutics, with one moving from $105 to $150, citing stronger conviction in Rezpeg's durability data in Atopic Dermatitis and alopecia areata, a clearer financing profile, and a more supportive catalyst path that is reflected in a higher fair value estimate of about $130 per share. Analyst Commentary Bullish Takeaways Bullish analysts point to the 52 week maintenance data from the REZOLVE AD study as reinforcing confidence in Rezpeg's durability, which they see as a key input to their higher fair value estimates.Uppdatering av berättelse • Feb 18
NKTR: Alopecia Areata Phase 2b Durability Will Drive Future Upside
Analysts have lifted their price target for Nektar Therapeutics by about $9, citing updated views on Rezpeg's durability, deepening clinical responses, and revised fair value assumptions as the key drivers of the change. Analyst Commentary Recent research updates show a cluster of upbeat views on Nektar Therapeutics, centered on Rezpeg's clinical profile and its potential role in Alopecia Areata and other indications.Analysartikel • Feb 12
Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up
Nektar Therapeutics ( NASDAQ:NKTR ) shares have had a really impressive month, gaining 81% after a shaky period...Uppdatering av berättelse • Feb 04
NKTR: Future Alopecia Areata Data Will Drive Upside Repricing Potential
Analysts have raised their fair value estimate for Nektar Therapeutics to $135 from $120, citing revised revenue growth assumptions, a lower future P/E multiple of about 165, and additional upside potential from Rezpeg in Alopecia Areata, which has an estimated $300 million in possible peak sales. Analyst Commentary Recent Street research has leaned positive on Nektar Therapeutics, with bullish analysts pointing to Rezpeg in Alopecia Areata as a key upside driver supporting higher valuation assumptions.Uppdatering av berättelse • Jan 20
NKTR: Alopecia Areata Phase 2b Data And Fast Track Will Drive Upside
Analysts have lifted their price target on Nektar Therapeutics from US$99 to US$121, citing Rezpeg's Phase 2b Alopecia Areata opportunity, its safety profile, durability potential, and an added 20% probability of success with about US$300m in estimated peak sales. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher US$121 price target as a reflection of added confidence in Rezpeg's Alopecia Areata opportunity and its potential to contribute meaningfully to Nektar's valuation over time.Uppdatering av berättelse • Jan 06
NKTR: Phase 2b Alopecia Data And Fast Track Status Will Drive Upside
Analysts have increased their price target for Nektar Therapeutics to $121 from $99, citing updated assumptions around Rezpeg, including new Alopecia Areata Phase 2b expectations, a clean safety profile, durability potential, and added value for future sales. They also highlighted the ongoing impact of Rezpeg related clinical data on how investors frame the separate Lilly litigation.Analysartikel • Dec 25
More Unpleasant Surprises Could Be In Store For Nektar Therapeutics' (NASDAQ:NKTR) Shares After Tumbling 25%
Nektar Therapeutics ( NASDAQ:NKTR ) shareholders that were waiting for something to happen have been dealt a blow with...Uppdatering av berättelse • Dec 17
NKTR: Upcoming Phase 2b Data Will Drive Upside Despite Litigation Uncertainty
Analysts have lifted their blended fair value estimate for Nektar Therapeutics from approximately $107 to $114 per share. They cite higher price targets driven by growing confidence in Rezpeg's Phase 2 data, its novel mechanism and safety profile, and incremental modeled peak sales, despite slightly more conservative long term revenue growth assumptions.Uppdatering av berättelse • Dec 02
NKTR: Late-Stage Clinical Data Will Drive Upside Despite Litigation Delays
Analysts have raised their price target for Nektar Therapeutics from approximately $94 to $107 per share. They cite growing confidence in the commercial potential of Rezpeg following recent positive clinical data and reinforced differentiation from competitors.Uppdatering av berättelse • Nov 18
NKTR: Positive Phase 2b Data Will Drive Momentum Amid Delayed Litigation
Analysts have raised their price target for Nektar Therapeutics from $69 to $99 per share. They cite recent positive clinical data and a stronger outlook for Rezpeg's competitive position in atopic dermatitis as the reasons for this adjustment.Uppdatering av berättelse • Nov 03
NKTR: Upcoming Phase 2b Data Readouts Will Drive Renewed Upside Momentum
Analysts have raised their price target for Nektar Therapeutics to $99, up from $69. This change is attributed to positive Phase 2b study results for rezpegaldesleukin and increased confidence in its commercial potential.Uppdatering av berättelse • Oct 20
Fast Track Immunology Asset Will Debut Amid Execution Risks
Nektar Therapeutics' analyst price target has been revised downward from $101.17 to $93.86 per share. Analysts cite recent clinical updates and ongoing litigation developments as key factors influencing their outlook.Uppdatering av berättelse • Sep 19
Fast Track Immunology Asset Will Debut Amid Execution Risks
Nektar Therapeutics’ consensus price target has increased to $101.17, driven by positive Phase 2b REZOLVE-AD results for rezpegaldesleukin, which demonstrated robust efficacy and safety in atopic dermatitis, supporting increased conviction in its differentiated clinical and commercial profile. Analyst Commentary Bullish analysts are raising price targets following positive Phase 2b REZOLVE-AD data for rezpegaldesleukin, with all primary and secondary endpoints met and robust efficacy and safety demonstrated in moderate-to-severe atopic dermatitis.Analysartikel • Aug 28
Nektar Therapeutics' (NASDAQ:NKTR) 28% Share Price Surge Not Quite Adding Up
Nektar Therapeutics ( NASDAQ:NKTR ) shares have continued their recent momentum with a 28% gain in the last month...Analysartikel • Jun 11
Nektar Therapeutics (NASDAQ:NKTR) Shares Fly 29% But Investors Aren't Buying For Growth
Nektar Therapeutics ( NASDAQ:NKTR ) shareholders are no doubt pleased to see that the share price has bounced 29% in...Analysartikel • May 15
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be
Market forces rained on the parade of Nektar Therapeutics ( NASDAQ:NKTR ) shareholders today, when the analysts...Analysartikel • May 11
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's shaping up to be a tough period for Nektar Therapeutics ( NASDAQ:NKTR ), which a week ago released some...Analysartikel • Apr 04
Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding
To the annoyance of some shareholders, Nektar Therapeutics ( NASDAQ:NKTR ) shares are down a considerable 29% in the...
Ny berättelse • Apr 03
Phase IIb Data And FDA Fast-Track Will Spur Mixed Prospects
Fast-track designation and strategic partnerships could expedite REZPEG's market entry, enhancing near-term revenue and profit margins.Analysartikel • Feb 10
Lacklustre Performance Is Driving Nektar Therapeutics' (NASDAQ:NKTR) 34% Price Drop
To the annoyance of some shareholders, Nektar Therapeutics ( NASDAQ:NKTR ) shares are down a considerable 34% in the...Analysartikel • Dec 06
Why Investors Shouldn't Be Surprised By Nektar Therapeutics' (NASDAQ:NKTR) 27% Share Price Plunge
Nektar Therapeutics ( NASDAQ:NKTR ) shareholders won't be pleased to see that the share price has had a very rough...Analysartikel • Oct 18
Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking
It's not a stretch to say that Nektar Therapeutics' ( NASDAQ:NKTR ) price-to-sales (or "P/S") ratio of 2.9x seems quite...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 47 | -409 | -337 | N/A | 9 |
| 12/31/2027 | 37 | -356 | -270 | N/A | 10 |
| 12/31/2026 | 41 | -250 | -186 | N/A | 10 |
| 3/31/2026 | 56 | -158 | N/A | N/A | N/A |
| 12/31/2025 | 55 | -164 | -209 | -209 | N/A |
| 9/30/2025 | 63 | -121 | -190 | -190 | N/A |
| 6/30/2025 | 75 | -122 | -186 | -185 | N/A |
| 3/31/2025 | 87 | -133 | -178 | -177 | N/A |
| 12/31/2024 | 98 | -119 | -177 | -176 | N/A |
| 9/30/2024 | 93 | -168 | -178 | -177 | N/A |
| 6/30/2024 | 93 | -177 | -175 | -175 | N/A |
| 3/31/2024 | 90 | -176 | -189 | -189 | N/A |
| 12/31/2023 | 90 | -276 | -193 | -193 | N/A |
| 9/30/2023 | 88 | -294 | -204 | -203 | N/A |
| 6/30/2023 | 88 | -307 | -245 | -244 | N/A |
| 3/31/2023 | 89 | -415 | -269 | -267 | N/A |
| 12/31/2022 | 92 | -368 | -310 | -304 | N/A |
| 9/30/2022 | 95 | -454 | -409 | -398 | N/A |
| 6/30/2022 | 96 | -525 | -430 | -416 | N/A |
| 3/31/2022 | 103 | -491 | -440 | -424 | N/A |
| 12/31/2021 | 102 | -524 | -428 | -413 | N/A |
| 9/30/2021 | 100 | -495 | -371 | -360 | N/A |
| 6/30/2021 | 105 | -474 | -321 | -311 | N/A |
| 3/31/2021 | 126 | -429 | -322 | -312 | N/A |
| 12/31/2020 | 153 | -444 | -321 | -313 | N/A |
| 9/30/2020 | 163 | -439 | -349 | -340 | N/A |
| 6/30/2020 | 163 | -429 | -368 | -356 | N/A |
| 3/31/2020 | 137 | -460 | -347 | -326 | N/A |
| 12/31/2019 | 115 | -441 | N/A | -329 | N/A |
| 9/30/2019 | 121 | -427 | N/A | -321 | N/A |
| 6/30/2019 | 119 | -424 | N/A | -324 | N/A |
| 3/31/2019 | 1,184 | 657 | N/A | 690 | N/A |
| 12/31/2018 | 1,193 | 681 | N/A | 718 | N/A |
| 9/30/2018 | 1,249 | 746 | N/A | 755 | N/A |
| 6/30/2018 | 1,374 | 903 | N/A | 920 | N/A |
| 3/31/2018 | 321 | -129 | N/A | -98 | N/A |
| 12/31/2017 | 308 | -97 | N/A | -80 | N/A |
| 9/30/2017 | 250 | -105 | N/A | -52 | N/A |
| 6/30/2017 | 133 | -209 | N/A | -173 | N/A |
| 3/31/2017 | 131 | -198 | N/A | -128 | N/A |
| 12/31/2016 | 165 | -154 | N/A | -117 | N/A |
| 9/30/2016 | 167 | -165 | N/A | -140 | N/A |
| 6/30/2016 | 191 | -130 | N/A | -126 | N/A |
| 3/31/2016 | 181 | -134 | N/A | -160 | N/A |
| 12/31/2015 | 231 | -81 | N/A | -73 | N/A |
| 9/30/2015 | 211 | -73 | N/A | -23 | N/A |
| 6/30/2015 | 284 | 6 | N/A | -55 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: NKTR förväntas förbli olönsam under de kommande 3 åren.
Resultat vs marknad: NKTR förväntas förbli olönsam under de kommande 3 åren.
Höga tillväxtresultat: NKTR förväntas förbli olönsam under de kommande 3 åren.
Intäkt vs marknad: NKTR s intäkter ( 34% per år) förväntas växa snabbare än US marknaden ( 11.7% per år).
Hög tillväxtintäkter: NKTR s intäkter ( 34% per år) förutspås växa snabbare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: NKTR förväntas bli olönsam om 3 år.
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/21 20:13 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Nektar Therapeutics bevakas av 31 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Richard Silver | Barclays |
| Aydin Huseynov | Benchmark Company |
| George Farmer | BMO Capital Markets Equity Research |